nach oben

Current Colorectal Cancer Reports

Erschienen in:

23.10.2021 | Systemic Therapies in Colorectal Cancer (SM Kazmi, Section Editor)

Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer

verfasst von: Sadaf Qureshi, Lyudmyla Berim, Patrick M. Boland

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aim of this paper is to summarize the current treatment landscape in metastatic colorectal cancer, as well as those on the horizon in the third-line and beyond settings.

Recent Findings

Herein, recent data regarding TAS-102, regorafenib, and novel anti-angiogenic agents are described. Data on chemotherapy re-challenge and EGFR re-challenge is reviewed. A summary of data on the use of BRAF-targeted therapies, HER-2-targeted therapies, rare fusions (NTRK, RET), MET amplification, and KRAS G12C is included, as well as a brief review on the current role of immune checkpoint inhibitors in metastatic colorectal cancer.

Summary

Multiple new agents are on the horizon. There is increasing relevance of next generation sequencing to look for rare targets, and potentially to assess tumor mutational burden. ctDNA appears to be a valuable asset which may guide the use of therapies in the re-challenge setting.

Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64.PubMedCrossRef

Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol. 2007;13(28):3806–15.PubMedPubMedCentralCrossRef

Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–8.PubMedCrossRef

NCC N. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Colon Cancer Version 2.2021. 2021.

Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22.PubMedPubMedCentralCrossRef

Kish T, Uppal P. Trifluridine/tipiracil (lonsurf) for the treatment of metastatic colorectal cancer. P T. 2016;41(5):314–25.PubMedPubMedCentral

Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–19.PubMedCrossRef

Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13(10):993–1001.PubMedCrossRef

Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, et al. Results of a randomized, double-blind, placebo-controlled, phase iii trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018;36(4):350–8.PubMedCrossRef

10.

Ettrich T.J. ST. Regorafenib. Small Molecules in Oncology Recent Results in Cancer Research. 211. August 2, 2018 ed: Springer, Cham; 2018.

11.

Grothey A, Prager G, Yoshino T. The mechanism of action of regorafenib in colorectal cancer: a guide for the community physician. Clin Adv Hematol Oncol. 2019;17(Suppl 12(8)):1–19.PubMed

12.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12.PubMedCrossRef

13.

Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–29.PubMedCrossRef

14.

Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016;16:412.PubMedPubMedCentralCrossRef

15.

Reiss KA, Yu S, Mamtani R, Mehta R, D’Addeo K, Wileyto EP, et al. Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study. J Clin Oncol. 2017;35(31):3575–81.PubMedPubMedCentralCrossRef

16.•

Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, et al. 2018 Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(8):1070–82. Novel study demonstrating effiacy of modified dosing schema with regorafenib.

17.

Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, et al. Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist. 2018;23(1):7–15.PubMedCrossRef

18.

Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, et al. Regorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparison. Clin Colorectal Cancer. 2017;16(2):e15–22.PubMedCrossRef

19.

Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Gravalos C, Benavides M, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63–72.PubMedCrossRef

20.

Vogel A, Hofheinz RD, Kubicka S, Arnold D. Treatment decisions in metastatic colorectal cancer - beyond first and second line combination therapies. Cancer Treat Rev. 2017;59:54–60.PubMedCrossRef

21.

Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, et al. Phase Ib/II study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study). Oncologist. 2020;25(12):e1855–63.PubMedCrossRef

22.

Cecchini M, Kortmansky JS, Cui C, Wei W, Thumar JR, Uboha NV, et al. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer. 2020.

23.

Varghese AM, Cardin DB, Hersch J, Benson AB, Hochster HS, Makris L, et al. Phase I study of trifluridine/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors. Clin Cancer Res. 2020;26(7):1555–62.PubMedCrossRef

24.

Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.PubMedCrossRef

25.

Matsuda C, Honda M, Tanaka C, Fukunaga M, Ishibashi K, Munemoto Y, et al. Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). Int J Clin Oncol. 2016;21(3):566–72.PubMedCrossRef

26.

Costa T, Nunez J, Felismino T, Boente L, Mello C. REOX: evaluation of the efficacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center study. Clin Colorectal Cancer. 2017;16(4):316–23.PubMedCrossRef

27.

Yin J, Cohen R, Jin Z, Liu H, Pederson L, Adams R, et al. Prognostic and predictive impact of primary tumor sidedness for previously untreated advanced colorectal cancer. J Natl Cancer Inst. 2021.

28.

Karani A, Felismino TC, Diniz L, Macedo MP, Silva VSE, Mello CA. Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis Ecancermedicalscience. 2020;14:1069.PubMed

29.

Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012;17(1):14.PubMedPubMedCentralCrossRef

30.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):827.PubMedCrossRef

31.••

Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243–9. Important analysis providing insight on decay of resistant clones following EGFR targeted therapy.

32.

Rossini D, Germani MM, Pagani F, Pellino A, Dell’Aquila E, Bensi M, et al. Retreatment with anti-EGFR antibodies in metastatic colorectal cancer patients: a multi-institutional analysis. Clin Colorectal Cancer. 2020;19(3):191-9 e6.PubMedCrossRef

33.••

Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343–50. Key study demonstrating efficacy of re-challenge and potential value of ctDNA.

34.••

Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021. Recent study reinforcing value of ctDNA in predicting efficacy of EGFR re-challenge.

35.

Sartore-Bianchi A PF, Lonardi S, Mussolin B, Rua F, Fenocchio E, et al. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: the CHRONOS trial. Journal of Clinical Oncology. 2021;39, no. 15_suppl 3506.

36.

Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3523–9.PubMedCrossRef

37.

Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37.PubMedCrossRef

38.

Bennouna J, Hiret S, Bertaut A, Bouche O, Deplanque G, Borel C, et al. Continuation of bevacizumab vs cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal cancer: the UNICANCER PRODIGE18 randomized clinical trial. JAMA Oncol. 2019;5(1):83–90.PubMedCrossRef

39.

Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol. 2015;26(4):724–30.PubMedCrossRef

40.

Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635–45.PubMedPubMedCentralCrossRef

41.

Cao J, Zhang J, Peng W, Chen Z, Fan S, Su W, et al. A phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(2):259–69.PubMedCrossRef

42.••

Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO Randomized clinical trial. JAMA. 2018;319(24):2486–96. Pivotal phase III study demonstrating efficacy of fruquintinib in Asian population.

43.

Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol. 2017;18(9):1172–81.PubMedCrossRef

44.

Yamazaki K KY, Shinozaki E, Hara H, Komatsu Y, Nishina T, et al. A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410). Ann Oncol. 2017;28, suppl_5.

45.

Boland PM FM, Lim D, Attwood K, Tan W, Mastri M, et al. A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer. J Clin Oncol. 2018;36, no. 15_suppl.

46.••

Pfeiffer P, Yilmaz M, Moller S, Zitnjak D, Krogh M, Petersen LN, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated open-label randomised phase 2 trial. Lancet Oncol. 2020;21(3):412–20. Randomized study demonstrating efficacy of adding anti-angiogenic therapy to fluoropyrimidine in 3rd-line setting.

47.

Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303.PubMedPubMedCentralCrossRef

48.

Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358–73.PubMedCrossRef

49.

Nowak JA. HER2 in colorectal carcinoma: are we there yet? Surg Pathol Clin. 2020;13(3):485–502.PubMedCrossRef

50.

Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8(49):86356–68.PubMedPubMedCentralCrossRef

51.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3(99):99ra86.PubMedPubMedCentralCrossRef

52.

Jeong JH, Kim J, Hong YS, Kim D, Kim JE, Kim SY, et al. HER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF. Clin Colorectal Cancer. 2017;16(3):e147–52.PubMedCrossRef

53.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–23.PubMedCrossRef

54.

Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist. 2019;24(10):1395–402.PubMedPubMedCentralCrossRef

55.

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329–59.PubMedCrossRef

56.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46.PubMedCrossRef

57.

Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–30.PubMedPubMedCentralCrossRef

58.

Nakamura Y, Okamoto W, Kato T, Hasegawa H, Kato K, Iwasa S, et al. 526PDTRIUMPH: primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study. Annals of Oncology. 2019;30.

59.

Strickler JH ZT, Ou FS, Cercek A, Wu C, Sanchez FA, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial. Ann Oncol. 2019;30, suppl_5.

60.••

Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25(10):3046–53. Novel ctDNA analysis demonstrating predictive capacity for HER-2-targeted therapy.

61.

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30.PubMedCrossRef

62.

Siena S, Bartolomeo MD, Raghav KPS, Masuishi T, Loupakis F, Kawakami H, et al. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. Journal of Clinical Oncology. 2020;38(15_suppl):4000.CrossRef

63.

Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol. 2015;6(6):660–7.PubMedPubMedCentral

64.

Paton EL, Turner JA, Schlaepfer IR. Overcoming resistance to therapies targeting the MAPK pathway in BRAF-mutated tumours. J Oncol. 2020;2020:1079827.PubMedPubMedCentralCrossRef

65.

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–36.PubMedPubMedCentralCrossRef

66.

Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227–35.PubMedPubMedCentralCrossRef

67.

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–3.PubMedCrossRef

68.

Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol. 2015;33(34):4023–31.PubMedPubMedCentralCrossRef

69.

Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, et al. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 2016;6(12):1352–65.PubMedPubMedCentralCrossRef

70.

Tabernero J, Geel RV, Guren TK, Yaeger RD, Spreafico A, Faris JE, et al. Phase results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF mutant colorectal cancer (BRAFm CRC). Journal of Clinical Oncology. 2016;34(15_suppl):3544.CrossRef

71.••

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–43. First-phase III trial demonstrating efficacy of multiagent BRAF targeted approach in mCRC.

72.

Kopetz S, Grothey A, Cutsem EV, Yaeger R, Wasan HS, Yoshino T, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer Updated survival results from a randomized. three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACCON CRC). Journal of Clinical Oncology. 2020;38(15_suppl):4001.CrossRef

73.

Ricciuti B, Genova C, Crino L, Libra M, Leonardi GC. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. Onco Targets Ther. 2019;12:3171–9.PubMedPubMedCentralCrossRef

74.•

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9. Key trial of larotrectinib demonstrating pan-cancer efficacy.

75.

Pagani F, Randon G, Guarini V, Raimondi A, Prisciandaro M, Lobefaro R, et al. The landscape of actionable gene fusions in colorectal cancer. Int J Mol Sci. 2019;20(21).

76.

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400–9.PubMedPubMedCentralCrossRef

77.

Braud FGD, Niger M, Damian S, Bardazza B, Martinetti A, Pelosi G, et al. Alka-372-001: first-in-human, phase I study of entrectinib - an oral pan-trk, ROS1, and ALK inhibitor - in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33(15):2517.CrossRef

78.

Patel MR, Bauer TM, Liu SV, Drilon AE, Wheler JJ, Shaw AT, et al. STARTRK-1: phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33(15):2596.CrossRef

79.

Solomon JP, Hechtman JF. Detection of NTRK fusions: merits and limitations of current diagnostic platforms. Cancer Res. 2019;79(13):3163–8.PubMedPubMedCentralCrossRef

80.

Subbiah V KB, Bauer T, McCoach C, Falchook G, Takeda M, et al. Abstract CT011: efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers. Cancer Res July 1 2021 (81) (13 Supplement) CT011. 2021.

81.

He X, Jiao XD, Liu K, Qin BD, Wu Y, Ling Y, et al. Clinical responses to crizotinib, alectinib, and lorlatinib in a metastatic colorectal carcinoma patient with ALK gene rearrangement: a case report. Jco Precis Oncol. 2021;5.

82.

Hsiao SY, He HL, Weng TS, Lin CY, Chao CM, Huang WT, et al. Colorectal cancer with EML4-ALK fusion gene response to alectinib: a case report and review of the literature. Case Rep Oncol. 2021;14(1):232–8.PubMedPubMedCentralCrossRef

83.

Zhang M, Li G, Sun X, Ni S, Tan C, Xu M, et al. MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma. Hum Pathol. 2018;77:108–15.PubMedCrossRef

84.

Kwak Y, Yun S, Nam SK, Seo AN, Lee KS, Shin E, et al. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer. J Transl Med. 2017;15(1):167.PubMedPubMedCentralCrossRef

85.

Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies. Clin Cancer Res. 2019;25(23):6899–908.PubMedPubMedCentralCrossRef

86.

Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, et al. Phase 1 study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts. Cancer Sci. 2020;111(2):536–47.PubMedCrossRef

87.

Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, et al. First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors. Clin Cancer Res. 2020;26(6):1237–46.PubMedCrossRef

88.

Delord JP, Argiles G, Fayette J, Wirth L, Kasper S, Siena S, et al. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. Invest New Drugs. 2020;38(6):1774–83.PubMedCrossRef

89.

Araujo LH, Souza BM, Leite LR, Parma SAF, Lopes NP, Malta FSV, et al. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer. BMC Cancer. 2021;21(1):193.PubMedPubMedCentralCrossRef

90.••

Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207–17. Initial phase I trial of KRAS G12C inhibitor demonstrating variable efficacy across tumor types.

91.

Johnson ML OS, Barve M, Rybki II, Papadopoulos KP, Leal TA, et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation. Eur J Cancer 138S2 (2020) S1–S62. 2020.

92.•

Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer. Cancer Discov. 2020;10(8):1129–39. Critical pre-clinical data paving the way for combinatorial approaches in KRAS G12C-mutated mCRC.

93.

Overman MJ, Ernstoff MS, Morse MA. Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management. Am Soc Clin Oncol Educ Book. 2018;38:239–47.PubMedCrossRef

94.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.PubMedPubMedCentralCrossRef

95.

Le DT, Kim TW, Van Cutsem E, Geva R, Jager D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–9. Important follow-up study evaluating the efficacy of pembrolizumab in pretreated MSI-H mCRC.

96.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.PubMedPubMedCentralCrossRef

97.

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65.PubMedCrossRef

98.

Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021.

99.

Meiri E, Garrett-Mayer E, Halabi S, Mangat PK, Shrestha S, Ahn ER, et al. Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol. 2020;38(4_suppl):133.CrossRef

100.

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1(3):207–16.PubMedCrossRef

101.

Silberman R, Steiner DF, Lo AA, Gomez A, Zehnder JL, Chu G, et al. Complete and prolonged response to immune checkpoint blockade in POLE-mutated colorectal cancer. JCO Precis Oncol. 2019;3:1–5.PubMed

102.

Chen J, Lou H. Complete response to pembrolizumab in advanced colon cancer harboring somatic POLE F367S mutation with microsatellite stability status: a case study. Onco Targets Ther. 2021;14:1791–6.PubMedPubMedCentralCrossRef

103.

Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J Natl Compr Canc Netw. 2017;15(2):142–7.PubMedCrossRef

104.

Huyghe N, Baldin P, Van den Eynde M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterol Rep (Oxf). 2020;8(1):11–24.CrossRef

105.

Rousseau BJCBI, Pasmant E, et al. High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated mismatch repair proficient (MMRp) advanced tumours. Annal Oncol. 2020;31(supp1_4):S462–504.

106.

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–83.PubMedPubMedCentralCrossRef

Titel: Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer
verfasst von: Sadaf Qureshi
Lyudmyla Berim
Patrick M. Boland
Publikationsdatum: 23.10.2021
Verlag: Springer US
Erschienen in: Current Colorectal Cancer Reports / Ausgabe 6/2021
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-021-00469-4

Neu im Fachgebiet Onkologie

17.04.2024 | Mammakarzinom | Nachrichten

Springer Medizin

Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

The Role of Ablative Radiotherapy to Liver Oligometastases from Colorectal Cancer

Imaging Advances on CT and MRI in Colorectal Cancer

Current Trends in the Treatment of Locally Advanced Rectal Cancer: Where We Are and How We Got Here

Recent Advances in Functional MRI to Predict Treatment Response for Locally Advanced Rectal Cancer

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie